Buzyn A - Search Results

1

FADD adaptor in cancer.

Tourneur L, Buzyn A, Chiocchia G. Tourneur L, et al. Among authors: buzyn a. Med Immunol. 2005 Feb 17;4(1):1. doi: 10.1186/1476-9433-4-1. Med Immunol. 2005. PMID: 15717929 Free PMC article.

2

Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes.

Buzyn A, Ostankovitch M, Zerbib A, Kemula M, Connan F, Varet B, Guillet JG, Choppin J. Buzyn A, et al. Eur J Immunol. 1997 Aug;27(8):2066-72. doi: 10.1002/eji.1830270834. Eur J Immunol. 1997. PMID: 9295046

3

IL-7 sensitizes human pre-B cells but not pro-B cells to Fas/APO-1 (CD95)-mediated apoptosis.

Levy Y, Benlagha K, Buzyn A, Colombel M, Brouet JC, Lassoued K. Levy Y, et al. Among authors: buzyn a. Clin Exp Immunol. 1997 Nov;110(2):329-35. doi: 10.1111/j.1365-2249.1997.tb08336.x. Clin Exp Immunol. 1997. PMID: 9367421 Free PMC article.

4

IFN regulatory factor-2 cooperates with STAT1 to regulate transporter associated with antigen processing-1 promoter activity.

Rouyez MC, Lestingi M, Charon M, Fichelson S, Buzyn A, Dusanter-Fourt I. Rouyez MC, et al. Among authors: buzyn a. J Immunol. 2005 Apr 1;174(7):3948-58. doi: 10.4049/jimmunol.174.7.3948. J Immunol. 2005. PMID: 15778351

5

Absence or low expression of fas-associated protein with death domain in acute myeloid leukemia cells predicts resistance to chemotherapy and poor outcome.

Tourneur L, Delluc S, Lévy V, Valensi F, Radford-Weiss I, Legrand O, Vargaftig J, Boix C, Macintyre EA, Varet B, Chiocchia G, Buzyn A. Tourneur L, et al. Among authors: buzyn a. Cancer Res. 2004 Nov 1;64(21):8101-8. doi: 10.1158/0008-5472.CAN-04-2361. Cancer Res. 2004. PMID: 15520222

6

DC-based vaccine loaded with acid-eluted peptides in acute myeloid leukemia: the importance of choosing the best elution method.

Delluc S, Tourneur L, Fradelizi D, Rubio MT, Marchiol-Fournigault C, Chiocchia G, Buzyn A. Delluc S, et al. Among authors: buzyn a. Cancer Immunol Immunother. 2007 Jan;56(1):1-12. doi: 10.1007/s00262-006-0170-6. Epub 2006 May 5. Cancer Immunol Immunother. 2007. PMID: 16676183

7

Membrane-bound Fas (Apo-1/CD95) ligand on leukemic cells: A mechanism of tumor immune escape in leukemia patients.

Buzyn A, Petit F, Ostankovitch M, Figueiredo S, Varet B, Guillet JG, Ameisen JC, Estaquier J. Buzyn A, et al. Blood. 1999 Nov 1;94(9):3135-40. Blood. 1999. PMID: 10556200

8

Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response.

Delluc S, Hachem P, Rusakiewicz S, Gaston A, Marchiol-Fournigault C, Tourneur L, Babchia N, Fradelizi D, Regnault A, Sang KH, Chiocchia G, Buzyn A. Delluc S, et al. Among authors: buzyn a. Cancer Immunol Immunother. 2009 Oct;58(10):1669-77. doi: 10.1007/s00262-009-0678-7. Epub 2009 Feb 19. Cancer Immunol Immunother. 2009. PMID: 19225777

9

[Outlook for cellular adoptive or vaccine immunotherapy for chronic myeloid leukemia].

Buzyn A, Ostankovitch M, Varet B, Guillet JG. Buzyn A, et al. Hematol Cell Ther. 1998 Oct;40(5):222-3. Hematol Cell Ther. 1998. PMID: 9844815 French. No abstract available.

10

Antileukemic HLA-restricted T-cell clones generated with naturally processed peptides eluted from acute myeloblastic leukemia blasts.

Ostankovitch M, Buzyn A, Bonhomme D, Connan F, Bouscary D, Heshmati F, Dreyfus F, Choppin J, Guillet JG. Ostankovitch M, et al. Among authors: buzyn a. Blood. 1998 Jul 1;92(1):19-24. Blood. 1998. PMID: 9639494

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results